The VITALITY-HFpEF trial (Evaluate the Efficacy and Safety of the Oral sGC Stimulator Vericiguat to Improve Physical Functioning in Daily Living Activities of Patients With Heart Failure and Preserved Ejection Fraction) is designed to determine the efficacy and safety of a novel oral soluble guanylate cyclase stimulator, vericiguat, on quality of life and exercise tolerance in heart failure patients with preserved ejection fraction (HFpEF)
The VITALITY-HFpEF study was presented on June 12, 2020 during HFA Discoveries, an online initiative from the European Society of Cardiology Heart Failure Association.
Rationale and Design of the VITALITY-HFpEF Trial.
Butler J, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O’Connor CM, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, Wu Y, Carvalho F, Bamber L, Blaustein RO, Roessig L, Armstrong PW.
Circ Heart Fail. 2019 May;12:e005998. doi: 10.1161/CIRCHEARTFAILURE.119.005998.
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O’Connor CM, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, She L, Vlajnic V, Carvalho F, Bamber L, Blaustein RO, Roessig L, Butler J; VITALITY-HFpEF Study Group.
JAMA. 2020 Oct;324:1512-1521. doi: 10.1001/jama.2020.15922.
Defining Changes in Physical Limitation From the Patient Perspective: Insights From the VITALITY-HFpEF Randomized Trial.
Butler J, Spertus JA, Bamber L, Khan MS, Roessig L, Vlajnic V, Norquist JM, Anstrom KJ, Blaustein RO, Lam CSP, Armstrong PW; VITALITY-HFpEF Study Group.
Eur J Heart Fail. 2022 Mar. doi: 10.1002/ejhf.2481.